Status:
COMPLETED
Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic Sclerosis
Lead Sponsor:
University of Michigan
Collaborating Sponsors:
Pfizer
Conditions:
Systemic Sclerosis
Eligibility:
FEMALE
18-99 years
Brief Summary
This study is to determine if subjects with .systemic sclerosis have stimulatory autoantibodies to the PDGF receptor and to confirm activation (phosphorylation) of the PDGF receptor in skin sites with...
Detailed Description
Pilot study to assess whether patients with systemic sclerosis have stimulatory autoantibodies to the PDGF receptor and to confirm activation (phosphorylation) of the PDGF receptor in skin sites with ...
Eligibility Criteria
Inclusion
- Fulfill the American College of Rheumatology criteria for systemic sclerosis or:
- Have no diseases that result in primary fibrosis of an organ system, including the skin and do not have an autoimmune disease
Exclusion
- If the subject has systemic sclerosis resulting from an environmental exposure
- If the subject has an autoimmune disease excluding scleroderma
- If the subject has an active infection (including, but not limited to hepatitis B, hepatitis C and HIV)
- If the subject has been treated with cyclophosphamide in the past 8 weeks.
- If the subject is prone to bleeding because they are on medications that thin the blood or have a low platelet count.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00667134
Start Date
March 1 2008
End Date
February 1 2012
Last Update
October 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan Medical School
Ann Arbor, Michigan, United States, 48103